Jacob Chacko - 23 Mar 2022 Form 4 Insider Report for Oric Pharmaceuticals, Inc. (ORIC)

Role
President and CEO, Director
Signature
/s/ Christian Kuhlen, attorney-in-fact
Issuer symbol
ORIC
Transactions as of
23 Mar 2022
Net transactions value
+$1,723,708
Form type
4
Filing time
25 Mar 2022, 18:42:26 UTC
Previous filing
02 Feb 2022
Next filing
13 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORIC Common Stock Purchase $1,280,878 +257,127 +9696% $4.98 259,779 23 Mar 2022 Direct F1
transaction ORIC Common Stock Purchase $215,660 +42,873 +17% $5.03 302,652 24 Mar 2022 Direct F2
transaction ORIC Common Stock Purchase $227,170 +50,000 +17% $4.54 352,652 25 Mar 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average share price of an aggregate total of 257,127 shares purchased in the price range of $4.73 to $5.10 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F2 Represents the weighted average share price of an aggregate total of 42,873 shares purchased in the price range of $5.03 to $5.05 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $4.455 to $4.60 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.